Treatment

UBT251 clinical trials

Active studies that list UBT251 as an intervention or treatment.

8active studies

6recruiting now

11countries represented

70largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 1

A Research Study Looking Into How UBT251 Works With Birth Control Tablets and Emptying of the Stomach in Women With Excess Body Weight Not Able to Become Pregnant

Overweight, ObesityCondition

UBT251, Oral contraceptiveTreatment

Canada1 locations

Novo Nordisk A/SSponsor

Updated 2026-08-25 · NCT07710729See eligibility →

Recruiting nowPhase 1

Phase I Drug-Drug Interaction Study of UBT251 Injection in Participants With Overweight or Obesity

Drug Drug Interaction (DDI), Pharmacokinetics and PharmacodynamicsCondition

UBT251, Metformin hydrochlorideTreatment

China1 locations

The United Bio-Technology (Hengqin) Co., Ltd.Sponsor

Updated 2026-08-25 · NCT07785934See eligibility →

Recruiting nowPhase 1

A Research Study on How UBT251 Affects Levels of Midazolam, Caffeine and Warfarin in the Blood of Participants With Excess Body Weight

Obesity, OverweightCondition

UBT251, Cocktail (Warfarin/Caffeine/Midazolam)Treatment

United States1 locations

Novo Nordisk A/SSponsor

Updated 2026-08-18 · NCT07710768See eligibility →

Recruiting nowPhase 2

A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes

Diabetes Mellitus, Type 2Condition

UBT251, UBT251 PlaceboTreatment

Australia, Germany70 locations

Novo Nordisk A/SSponsor

Updated 2026-08-10 · NCT07668388See eligibility →

Recruiting nowPhase 2

A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity

Overweight, ObesityCondition

UBT251, PlaceboTreatment

Canada, United States3 locations

Novo Nordisk A/SSponsor

Updated 2026-04-21 · NCT07395687See eligibility →

Recruiting nowPhase 2

UBT251 Injection Phase II Clinical Study (CKD)

Obesity &Amp; Overweight, Chronic Kidney DiseaseCondition

UBT251, UBT251Treatment

China1 locations

The United Bio-Technology (Hengqin) Co., Ltd.Sponsor

Updated 2025-11-25 · NCT07134335See eligibility →

Opening soonPhase 3

UBT251 Injection Phase Ⅲ Study (OSA-PAP)

Obstructive Sleep Apnea, ObesityCondition

UBT251, UBT251Treatment

Locations pending0 locations

The United Bio-Technology (Hengqin) Co., Ltd.Sponsor

Updated 2026-09-08 · NCT07806851See eligibility →

Opening soonPhase 3

UBT251 Injection Phase Ⅲ Study (OSA-NPAP)

Obstructive Sleep Apnea, ObesityCondition

UBT251, UBT251Treatment

Locations pending0 locations

The United Bio-Technology (Hengqin) Co., Ltd.Sponsor

Updated 2026-08-25 · NCT07767942See eligibility →

Related treatments

Placebo421 Tirzepatide119 Semaglutide91 Control30 Exercise27 Orforglipron21

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.